TRIVENI
Live / Applied — Second extension granted (statement of use) (as of 01 Oct 2025)
What this means for you
Not registered yet, but its 24 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97810745
- Mark type
- Stylized text
- Filed
- 24 Feb 2023
- Published for opposition
- 15 Oct 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic and biopharmaceutical agents for treatment of immunological and inflammatory disorders; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for treatment of genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune/autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; biological preparations, namely, antibodies for medical purposes
- Class 042 — Scientific and technological services: Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and discovery; research and analysis services using machine learning analytics relating to drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents; research services in the fields of genomic analysis; scientific research, namely, genomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; scientific research, namely, DNA analysis and sequencing services for scientific and research purposes; scientific research, development and scientific research consultancy in the field of genomics; medical research, namely, compiling data for research purposes in the field of genomics
Owner
- TRIVENI BIO, INC., WALTHAM, MA, US
- TRIVENI BIO, INC., WALTHAM, MA, US
- Amagma, Inc., Waltham, MA, US
Prosecution history
- 02 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 2 GRANTED
- 01 Oct 2025 — SOU EXTENSION 2 FILED
- 01 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 May 2025 — SOU EXTENSION 1 GRANTED
- 27 May 2025 — SOU EXTENSION 1 FILED
- 27 May 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Oct 2024 — PUBLISHED FOR OPPOSITION
- 25 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Sept 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Sept 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE